Natalizumab drug holiday in multiple sclerosis: Poorly tolerated

Annals of Neurology

Volumn 68, Issue 3, 2010, Pages 392-395

  Killestein, Joep ^a   Vennegoor, Anke ^a   Strijbis, Eva M ^a   Seewann, Alexandra ^a   Van Oosten, Bob W ^a   Uitdehaag, Bernard M J ^a   Polman, Chris H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; NATALIZUMAB; ALPHA4 INTEGRIN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE EXACERBATION; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTEGRIN ALPHA4; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 77956385153     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22074     Document Type: Article

References (11)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing MS. N Engl J Med 2006;354:899-910. (Pubitemid 43313657)
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing MS. N Engl J Med 2006;354:911-923.
3. European Medicines Agency. Questions and answers on the review of Tysabri (natalizumab). Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/ tysabri/Tysabri-A20-29-Q&A.pdf Accessed January 21, 2010.
4. US Food and Drug Administration. Information on natalizumab (marketed as Tysabri). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm107198.htm. Accessed February 1, 2010.
5. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selecting and monitoring. Lancet Neurol 2007;6:431-441. (Pubitemid 46551850)
6. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009;361:1067-1074.
7. Rudick RA, Polman CH, O'Connor PW, et al. Evaluation of natalizumab treatment on the presence of JC virus in blood and urine from MS patients. Mult Scler 2009;15(suppl 9):S274-S275.
8. Varnier OE, McDermott JL, Giacomazzi CG, et al. Non invasive surveillance of JCV reactivation in blood and urine from natalizumab treated MS patients, blood donors and immunocompromised patients identifies five PML cases in HIV and congenital immunodeficiency patients. Mult Scler 2009;15(suppl 9):S276-S277.
9. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009;8:28-31.
10. Hauser SL, Johnston SC. Balancing risk and reward: the question of natalizumab. Ann Neurol 2009;66:A7-A8.
11. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009;72:402-409.